Coegin Pharma AB's shares dual-listed on Börse Stuttgart as of today, July 1, 2024

Coegin Pharma AB is pleased to announce that NGM's application process for the dual-listing of the company's shares on Börse Stuttgart is now completed. The first trading day on Börse Stuttgart is today, July 1, 2024.

This dual-listing is part of the Nordic Growth Market NGM AB ("NGM") Reach program, which leverages the primary listing in Sweden and makes shares primarily listed on NGM available through the "Nordic Growth Market" segment on Börse Stuttgart. Participation in NGM Reach incurs no significant costs for Coegin Pharma AB.

Börse Stuttgart Group is the sixth-largest exchange group in Europe, with more than 2 million listed securities. This dual listing will provide Coegin Pharma with access to a broader network of investors through a truly European listing platform.

"We are pleased that our shares are now available to a broader investor base in Europe. We look forward to welcoming new shareholders and continuing our work on the pre-launch activities for our focus project on hair growth," says Jens Eriksson, CEO of Coegin Pharma.

Coegin's management will participate in a listing event in Stuttgart this fall. Communication activities to reach investors at Börse Stuttgart will also begin after the summer break.

In conjunction with the parallel listing on Börse Stuttgart, Coegin will start using English in its various communication channels to better reach an international audience. The company's website is already available in both Swedish and English.

For further information, please contact:
Jens Eriksson, CEO
Email: [email protected]
Phone: +46 72 221 24 21

This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.

About Coegin Pharma
Coegin Pharma is a Swedish biotechnology company with several innovative groundbreaking drug candidates and dermocosmetic products. The company's projects have great potential for treating patients with serious diseases such as cancer and heart attack, as well as improving the quality of life for people in need of cosmetic products for hair growth. The strategy is to create value by developing and commercializing dermocosmetic products in partnership with leading commercial players and by early out-licensing "first-in-class" drug candidates to major pharmaceutical companies. 

For further information: www.coeginpharma.com/en.